Table 1.
Distribution of the SULT1A1 rs9282861 genotypes in relation to the subject characteristics§
| rs9282861 genotype | ||||
|---|---|---|---|---|
| Characteristics | All subjects (n = 412) | GG (n = 121) | AG (n = 194) | AA (n = 97) |
| Age at diagnosis, years | ||||
| ≤ 39 | 37 (9.0) | 14 (37.8) | 15 (40.5) | 8 (21.6) |
| 40-49 | 98 (23.8) | 34 (34.7) | 40 (40.8) | 24 (24.5) |
| 50-59 | 104 (25.2) | 29 (27.9) | 51 (49.0) | 24 (23.1) |
| 60-69 | 65 (15.8) | 16 (24.6) | 36 (55.4) | 13 (20.0) |
| ≥ 70 | 108 (26.2) | 28 (25.9) | 52 (48.1) | 28 (25.9) |
| T stage (UICC)† | ||||
| 1 | 215 (52.2) | 59 (27.4) | 101 (47.0) | 55 (25.6) |
| 2 | 164 (39.8) | 56 (34.1) | 73 (44.5) | 35 (21.3) |
| 3 | 22 (5.3) | 3 (13.6) | 15 (68.2) | 4 (18.2) |
| 4 | 11 (2.7) | 3 (27.3) | 5 (45.5) | 3 (27.3) |
| Nodal status (UICC) | ||||
| N- | 247 (60.0) | 67 (27.1) | 117 (47.4) | 63 (25.5) |
| N+ | 165 (40.0) | 54 (32.7) | 77 (46.7) | 34 (20.6) |
| Stage (UICC) | ||||
| I | 165 (40.0) | 46 (27.9) | 79 (47.9) | 40 (24.2) |
| II | 210 (51.0) | 68 (32.4) | 92 (43.8) | 50 (23.8) |
| III | 37 (9.0) | 7 (18.9) | 23 (62.2) | 7 (18.9) |
| Oestrogen receptor status | ||||
| Positive | 310 (75.2) | 88 (28.4) | 146 (47.1) | 76 (24.5) |
| Negative | 89 (21.6) | 28 (31.5) | 45 (50.6) | 16 (18.0) |
| Unknown | 13 (3.2) | 5 (38.5) | 3 (23.1) | 5 (38.5) |
| Progesterone receptor status | ||||
| Positive | 247 (60.0) | 71 (28.7) | 113 (45.7) | 63 (25.5) |
| Negative | 150 (36.4) | 45 (30.0) | 76 (50.7) | 29 (19.3) |
| Unknown | 15 (3.6) | 5 (33.3) | 5 (33.3) | 5 (33.3) |
| Morphological type | ||||
| Ductal | 268 (65.0) | 75 (28.0) | 132 (49.3) | 61 (22.8) |
| Lobular | 70 (17.0) | 28 (40.0) | 27 (38.6) | 15 (21.4) |
| Other types | 74 (18.0) | 18 (24.3) | 35 (47.3) | 21 (28.4) |
| Adjuvant treatment | ||||
| Radiotherapy | 243 (59.0) | 74 (30.5) | 110 (45.3) | 59 (24.3) |
| Endocrine therapy | 106 (25.7) | 28 (26.4) | 56 (52.8) | 22 (20.8) |
| Tamoxifen | 88 (21.4) | 23 (26.1) | 45 (51.1) | 20 (22.7) |
| Toremifen | 17 (4.1) | 5 (29.4) | 11 (64.7) | 1 (5.9) |
| Chemotherapy | 80 (19.4) | 34 (42.5) | 31 (38.8) | 15 (18.8) |
| Vital Status | ||||
| Alive | 184 (44.7) | 50 (27.2) | 88 (47.8) | 46 (25.0) |
| No recurrence | 159 (38.6) | 41 (25.8) | 79 (49.7) | 39 (24.5) |
| Recurrence of breast cancer | 25 (6.1) | 9 (36.0) | 9 (36.0) | 7 (28.0) |
| Death | 228 (55.3) | 71 (31.1) | 106 (46.5) | 51 (22.4) |
| Breast cancer caused death | 112 (27.2) | 40 (35.7) | 49 (43.8) | 23 (20.5) |
| Death with other reasons | 116 (28.2) | 31 (26.7) | 57 (49.1) | 28 (24.1) |
§Values in the table are number of patients (%).
†UICC = International Union Against Cancer, TNM Classification of Malignant Tumours, Fourth, Fully Revised Edition